AUTHORS
Kai Shen, MD, Jie Wang2, He LI3, Jiazhuo Liu4, Bing Xiang5, Chuan He Sr, ????6, Chenlu Yang, PhD7, Yun Tang8, Ting MD, PhD Niu, MD, PhD9
AFFILIATIONS
1 West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 West China Hospital, Sichuan University, Chengdu, Sichuan, China
5 West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 West China Hospital, Sichuan University, Chengdu, Sichuan, China
7 West China Hospital, Sichuan University, Chengdu, Sichuan, China
8 West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 West China Hospital, Sichuan University, Chengdu, Sichuan, China
ABSTRACT
Background
Bruton's tyrosine kinase inhibitors (BTKis) are the standard first-line targeted therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, off-target effects and clinically significant adverse events (AEs) limit their clinical application. Orelabrutinib, a highly selective BTK inhibitor with linear pharmacokinetics, exhibits high selectivity for BTK kinase, distinguishing it from other BTKis (ibrutinib, acalabrutinib, and zanubrutinib). Although orelabrutinib is approved for CLL/SLL in China, real-world data evaluating its efficacy and safety in patients previously exposed to alternative BTKis remain scarce globally.
Aims
This study aimed to characterize the efficacy and safety of orelabrutinib monotherapy in BTKi-pretreated CLL/SLL patients.
Methods
This single-center retrospective study enrolled 21 patients with CLL/SLL who switched to orelabrutinib after prior BTKi therapy between January 1, 2022, and November 1, 2025. Data on demographics and clinical characteristics, treatment history, outcomes, and safety were collected and analyzed.
Results
Among the 21 patients (20 with CLL and 1 with SLL), the median age was 62 years (range, 42–78), and 52.4% (11/21) were male.38.1% had Binet stage C disease, 28.6% carried unmutated IGHV, and none harbored a confirmed TP53 mutation. All patients had an ECOG PS of 0–1; 14.3% (3/21) presented with bone marrow infiltration, and 19.0% (4/21) with splenomegaly.
Prior to orelabrutinib treatment, all patients had received at least one prior line of therapy (range,1-3): 11 patients received single-agent ibrutinib, 6 received single-agent zanubrutinib, and 4 received sequential ibrutinib followed by zanubrutinib. The median duration of prior ibrutinib therapy was 31.9 months (range, 3.3-66.7 months), while prior zanubrutinib exposure lasted a median of 6.8 months (range, 1–31 months). Reasons for switching included BTKi-related intolerable AEs (28.6%), persistent stable disease (SD) without deep remission (19.0%), confirmed disease progression (4.8%), and shared physician–patient treatment preference without toxicity or progression triggers (47.6%).
The median follow-up was 27.5 months, and patients received a median of 18 orelabrutinib cycles (150 mg, once daily; 28-day cycles; range, 2–54). All 21 patients were evaluable for response, yielding a best overall response rate (ORR) of 90.5% (19/21) and a complete remission (CR) rate of 38.1% (8/21). Serial deepening of response was observed: 3 patients converted from SD to partial remission (PR), 3 from SD to CR, and 3 from PR to CR, demonstrating the capacity for improved response depth after switching.Two patients required dose reduction to 100 mg once daily (one for grade 1 dizziness and one per clinical physician judgment). Three patients permanently discontinued orelabrutinib: one due to disease progression, one due to insufficient therapeutic response, and one by patient choice. Six distinct AE categories were documented. Hemorrhage (14.3%) and cardiac arrhythmia (4.8%) were the predominant toxicities associated with prior BTKi therapy; all patients who switched because of BTKi-related toxicities experienced complete resolution of baseline hemorrhage and arrhythmia after orelabrutinib initiation.
Conclusion
Orelabrutinib monotherapy demonstrated promising clinical efficacy and a favorable safety profile in BTKi-pretreated patients with CLL/SLL. Further larger-cohort studies are warranted to validate these findings.
DISCLOSURES
Kai Shen, MD: No relevant conflicts of interest to declare.